These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 9337346)

  • 41. Molecular detection of prostate cells in ejaculate and urethral washings in men with suspected prostate cancer.
    Clements JA; Rohde P; Allen V; Hyland VJ; Samaratunga ML; Tilley WD; Lavin MF; Gardiner RA
    J Urol; 1999 Apr; 161(4):1337-43. PubMed ID: 10081904
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The value of prostate-specific antigen levels in pelvic lymph nodes for diagnosing metastatic spread of prostate cancer.
    Shoskes DA; Trachtenberg J
    Can J Surg; 1993 Feb; 36(1):33-6. PubMed ID: 7680271
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prostate-specific membrane antigen.
    Fair WR; Israeli RS; Heston WD
    Prostate; 1997 Jul; 32(2):140-8. PubMed ID: 9215402
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Sheridan T; Herawi M; Epstein JI; Illei PB
    Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Laparoscopic pelvic lymph node dissection in the staging of prostate cancer.
    Stone NN; Stock RG
    Mt Sinai J Med; 1999 Jan; 66(1):26-30. PubMed ID: 9989102
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay.
    Katz AE; Olsson CA; Raffo AJ; Cama C; Perlman H; Seaman E; O'Toole KM; McMahon D; Benson MC; Buttyan R
    Urology; 1994 Jun; 43(6):765-75. PubMed ID: 7515202
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.
    Cagiannos I; Karakiewicz P; Eastham JA; Ohori M; Rabbani F; Gerigk C; Reuter V; Graefen M; Hammerer PG; Erbersdobler A; Huland H; Kupelian P; Klein E; Quinn DI; Henshall SM; Grygiel JJ; Sutherland RL; Stricker PD; Morash CG; Scardino PT; Kattan MW
    J Urol; 2003 Nov; 170(5):1798-803. PubMed ID: 14532779
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer.
    Queisser A; Hagedorn SA; Braun M; Vogel W; Duensing S; Perner S
    Mod Pathol; 2015 Jan; 28(1):138-45. PubMed ID: 24925052
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment.
    Ferrari AC; Stone NN; Kurek R; Mulligan E; McGregor R; Stock R; Unger P; Tunn U; Kaisary A; Droller M; Hall S; Renneberg H; Livak KJ; Gallagher RE; Mandeli J
    J Clin Oncol; 2006 Jul; 24(19):3081-8. PubMed ID: 16809733
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer.
    Schilling D; Schlemmer HP; Wagner PH; Böttcher P; Merseburger AS; Aschoff P; Bares R; Pfannenberg C; Ganswindt U; Corvin S; Stenzl A
    BJU Int; 2008 Aug; 102(4):446-51. PubMed ID: 18410442
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer.
    Ananias HJ; van den Heuvel MC; Helfrich W; de Jong IJ
    Prostate; 2009 Jul; 69(10):1101-8. PubMed ID: 19343734
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression of prostatic factors measured by reverse transcription polymerase chain reaction in human papillomavirus type 18 deoxyribonucleic acid immortalized prostate cell lines.
    Weijerman PC; Zhang Y; Shen J; Dubbink HJ; Romijn JC; Peehl DM; Schröder FH
    Urology; 1998 Apr; 51(4):657-62. PubMed ID: 9586625
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The use of RT-"nested" PCR of prostate specific antigen to detect hematogenous neoplastic cells in patients with prostate adenocarcinoma.
    Sardi I; Piazzini M; Ponchietti R; Fatini C; Di Loro F; Guazzelli R
    J Mol Med (Berl); 1997 Oct; 75(10):751-7. PubMed ID: 9382999
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predicting pelvic lymph node involvement in current-era prostate cancer.
    Rahman S; Cosmatos H; Dave G; Williams S; Tome M
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):906-10. PubMed ID: 21300478
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Positive prostate-specific antigen circulating cells detected by reverse transcriptase-polymerase chain reaction does not imply the presence of prostatic micrometastases.
    Thiounn N; Saporta F; Flam TA; Pages F; Zerbib M; Vieillefond A; Martin E; Debré B; Chevillard S
    Urology; 1997 Aug; 50(2):245-50. PubMed ID: 9255296
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in blood cells: implications for the detection of hematogenous prostate cells and standardization.
    Gala JL; Heusterspreute M; Loric S; Hanon F; Tombal B; Van Cangh P; De Nayer P; Philippe M
    Clin Chem; 1998 Mar; 44(3):472-81. PubMed ID: 9510850
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High occurrence of aberrant lymph node spread on magnetic resonance lymphography in prostate cancer patients with a biochemical recurrence after radical prostatectomy.
    Meijer HJ; van Lin EN; Debats OA; Witjes JA; Span PN; Kaanders JH; Barentsz JO
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1405-10. PubMed ID: 21640507
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer.
    Murphy GP; Troychak MJ; Cobb OE; Bowes VA; Kenny RJ; Barren RJ; Kenny GM; Ragde H; Holmes EH; Wolfert RL
    Prostate; 1997 Oct; 33(2):141-6. PubMed ID: 9316655
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
    Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
    Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular diagnostic tools for the detection of nodal micrometastases in prostate cancer patients undergoing radical prostatectomy with extended pelvic lymph node dissection: a prospective study.
    Vagnoni V; Schiavina R; Romagnoli D; Borghesi M; Passaretti G; Dababneh H; Concetti S; Martorana G
    Urologia; 2012 Dec; 79 Suppl 19():141-6. PubMed ID: 22865337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.